Non-TNFi Biologics Linked to Lower PsA Risk

Aug 12, 2026 · Published in: Rheumatology (Oxford, England)

Background Information

Non-TNFi biologics may lower PsA risk in psoriasis.

This study investigates how different biologic disease-modifying antirheumatic drugs (bDMARDs) used for psoriasis may influence the progression to psoriatic arthritis (PsA). Understanding this can help tailor treatment approaches to prevent PsA. Patients with psoriasis treated with non-tumor necrosis factor inhibitors (non-TNFi) bDMARDs had lower odds (OR range 0.16-0.25) and hazards (HR range 0.17-0.30) of developing PsA compared to those on TNFi. The findings suggest that selecting non-TNFi bDMARDs, such as IL-17 and IL-23 inhibitors, may reduce PsA risk. These results are based on a real-world cohort study, but applicability to pediatric cases needs separate investigation. Choosing non-TNFi bDMARDs could lower PsA progression risk in psoriasis patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kougkas N, Sotiriou E, Deligeorgakis D, Skepastianos V, Skouvaklidou E, Tsafis K, Vergou T, Michalakeas N, Papadimitriou I, Dimitroulas T, Fragoulis GE

Citation: Kougkas N, Sotiriou E, Deligeorgakis D, et al. Biologic DMARD class influences progression from psoriasis to PsA: A real-world cohort study. Rheumatology (Oxford, England). 2026. doi:10.1093/rheumatology/keag410

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.